JPRN-jRCT2080221407未知3 期
A double blind study of KRN125 compared to placebo for chemotherapy-induced neutropenia in breast cancer
Kyowa Hakko Kirin Co., Ltd.0 个研究点开始时间: 2011年3月22日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 70age old（—）
- 性别
- Female
入选标准
- •Written informed consent
- •- Diagnosed with stage I - III primary invasive breast cancer
- •- No prior chemotherapy
- •- Going to receive TC treatment regimen as adjuvant or neoadjuvant chemotherapy
- •- ECOG PS =< 2
- •- Appropriate bone marrow, hepatic and renal functions
排除标准
- •- Complication or anamnesis of cardiac disease, such as heart failure and severe arrhythmia
- •- Double cancer
- •- Primary hematologic disease such as myelodysplastic syndrome or aplastic anemia
- •- Undergoing interstitial pneumonia treatment
- •- Previous radiotherapy within 4 weeks of enrollment
研究者
相似试验
未知
3 期
A phase III, double blind, comparative study of KRN125JPRN-jRCT2080221357Kyowa Hakko Kirin Co., Ltd.
已完成
不适用
Terbutaline tocolysis for external cephalic version: a randomised comparison of the 250 µg versus 500 µg bolus doseISRCTN89932581niversity of Malaya Medical Centre (Malaysia)104
已完成
不适用
Randomized double-blind study for the effect of kosen-cha on obese subjectsHealthy volunteers with obesityJPRN-UMIN000020068niversity of Shizuoka60
已完成
2 期
Clinical study comparing the efficacy in the achievement of the remission (measured as reduction of proteinuria) and safety of two different doses of voclosporin and non active drug (placebo) in patients suffering from active lupus nephritisActive Lupus NephritisSLCTR/2015/001Aurinia Pharmaceuticals Inc.
进行中（未招募）
1 期
A double-blind, randomized study versus placebo of avdoralimab (IPH5401), an anti-C5aR antibody, in patients with COVID-19 induced pneumoniaCoronavirus infectionMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862EUCTR2020-001686-36-FRASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE168